GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Luoxin Pharmaceuticals Group Stock Co Ltd (SZSE:002793) » Definitions » Beneish M-Score

Luoxin Pharmaceuticals Group Stock Co (SZSE:002793) Beneish M-Score : -4.20 (As of May. 25, 2024)


View and export this data going back to 2016. Start your Free Trial

What is Luoxin Pharmaceuticals Group Stock Co Beneish M-Score?

The zones of discrimination for M-Score is as such:

An M-Score of equal or less than -1.78 suggests that the company is unlikely to be a manipulator.
An M-Score of greater than -1.78 signals that the company is likely to be a manipulator.

Good Sign:

Beneish M-Score -4.2 no higher than -1.78, which implies that the company is unlikely to be a manipulator.

The historical rank and industry rank for Luoxin Pharmaceuticals Group Stock Co's Beneish M-Score or its related term are showing as below:

SZSE:002793' s Beneish M-Score Range Over the Past 10 Years
Min: -30.62   Med: -1.75   Max: 24.71
Current: -4.2

During the past 13 years, the highest Beneish M-Score of Luoxin Pharmaceuticals Group Stock Co was 24.71. The lowest was -30.62. And the median was -1.75.


Luoxin Pharmaceuticals Group Stock Co Beneish M-Score Historical Data

The historical data trend for Luoxin Pharmaceuticals Group Stock Co's Beneish M-Score can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Luoxin Pharmaceuticals Group Stock Co Beneish M-Score Chart

Luoxin Pharmaceuticals Group Stock Co Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Beneish M-Score
Get a 7-Day Free Trial Premium Member Only Premium Member Only -1.59 -1.82 -2.14 -2.23 -4.28

Luoxin Pharmaceuticals Group Stock Co Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Beneish M-Score Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -30.62 -13.68 -3.29 -4.28 -4.20

Competitive Comparison of Luoxin Pharmaceuticals Group Stock Co's Beneish M-Score

For the Drug Manufacturers - Specialty & Generic subindustry, Luoxin Pharmaceuticals Group Stock Co's Beneish M-Score, along with its competitors' market caps and Beneish M-Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Luoxin Pharmaceuticals Group Stock Co's Beneish M-Score Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Luoxin Pharmaceuticals Group Stock Co's Beneish M-Score distribution charts can be found below:

* The bar in red indicates where Luoxin Pharmaceuticals Group Stock Co's Beneish M-Score falls into.



Luoxin Pharmaceuticals Group Stock Co Beneish M-Score Calculation

The M-score was created by Professor Messod Beneish. Instead of measuring the bankruptcy risk (Altman Z-Score) or business trend (Piotroski F-Score), M-score can be used to detect the risk of earnings manipulation. This is the original research paper on M-score.

The M-Score Variables:

The M-score of Luoxin Pharmaceuticals Group Stock Co for today is based on a combination of the following eight different indices:

M=-4.84+0.92 * DSRI+0.528 * GMI+0.404 * AQI+0.892 * SGI+0.115 * DEPI
=-4.84+0.92 * 0.363+0.528 * -0.0234+0.404 * 1.2007+0.892 * 1.1531+0.115 * 1
-0.172 * SGAI+4.679 * TATA-0.327 * LVGI
-0.172 * 0.7543+4.679 * -0.185947-0.327 * 0.9543
=-4.20

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

This Year (Mar24) TTM:Last Year (Mar23) TTM:
Total Receivables was ¥675 Mil.
Revenue was 688.729 + 537.362 + 571.052 + 593.026 = ¥2,390 Mil.
Gross Profit was 252.424 + 232.172 + 265.81 + 288.509 = ¥1,039 Mil.
Total Current Assets was ¥2,112 Mil.
Total Assets was ¥5,117 Mil.
Property, Plant and Equipment(Net PPE) was ¥1,590 Mil.
Depreciation, Depletion and Amortization(DDA) was ¥0 Mil.
Selling, General, & Admin. Expense(SGA) was ¥1,036 Mil.
Total Current Liabilities was ¥2,248 Mil.
Long-Term Debt & Capital Lease Obligation was ¥289 Mil.
Net Income was -36.662 + -431.627 + -102.625 + -36.651 = ¥-608 Mil.
Non Operating Income was 0 + 0 + 0 + 0 = ¥0 Mil.
Cash Flow from Operations was -96.08 + 149.943 + 184.101 + 105.994 = ¥344 Mil.
Total Receivables was ¥1,613 Mil.
Revenue was 662.426 + -182.072 + 626.811 + 965.734 = ¥2,073 Mil.
Gross Profit was 307.458 + -601.045 + -40.244 + 312.774 = ¥-21 Mil.
Total Current Assets was ¥3,701 Mil.
Total Assets was ¥7,055 Mil.
Property, Plant and Equipment(Net PPE) was ¥1,730 Mil.
Depreciation, Depletion and Amortization(DDA) was ¥0 Mil.
Selling, General, & Admin. Expense(SGA) was ¥1,192 Mil.
Total Current Liabilities was ¥3,200 Mil.
Long-Term Debt & Capital Lease Obligation was ¥464 Mil.




1. DSRI = Days Sales in Receivables Index

Measured as the ratio of Revenue in Total Receivables in year t to year t-1.

A large increase in DSR could be indicative of revenue inflation.

DSRI=(Receivables_t / Revenue_t) / (Receivables_t-1 / Revenue_t-1)
=(674.986 / 2390.169) / (1612.594 / 2072.899)
=0.282401 / 0.777941
=0.363

2. GMI = Gross Margin Index

Measured as the ratio of gross margin in year t-1 to gross margin in year t.

Gross margin has deteriorated when this index is above 1. A firm with poorer prospects is more likely to manipulate earnings.

GMI=GrossMargin_t-1 / GrossMargin_t
=(GrossProfit_t-1 / Revenue_t-1) / (GrossProfit_t / Revenue_t)
=(-21.057 / 2072.899) / (1038.915 / 2390.169)
=-0.010158 / 0.434662
=-0.0234

3. AQI = Asset Quality Index

AQI is the ratio of asset quality in year t to year t-1.

Asset quality is measured as the ratio of non-current assets other than Property, Plant and Equipment to Total Assets.

AQI=(1 - (CurrentAssets_t + PPE_t) / TotalAssets_t) / (1 - (CurrentAssets_t-1 + PPE_t-1) / TotalAssets_t-1)
=(1 - (2111.895 + 1590.382) / 5117.183) / (1 - (3701.003 + 1729.578) / 7055.301)
=0.276501 / 0.230284
=1.2007

4. SGI = Sales Growth Index

Ratio of Revenue in year t to sales in year t-1.

Sales growth is not itself a measure of manipulation. However, growth companies are likely to find themselves under pressure to manipulate in order to keep up appearances.

SGI=Sales_t / Sales_t-1
=Revenue_t / Revenue_t-1
=2390.169 / 2072.899
=1.1531

5. DEPI = Depreciation Index

Measured as the ratio of the rate of Depreciation, Depletion and Amortization in year t-1 to the corresponding rate in year t.

DEPI greater than 1 indicates that assets are being depreciated at a slower rate. This suggests that the firm might be revising useful asset life assumptions upwards, or adopting a new method that is income friendly.

DEPI=(Depreciation_t-1 / (Depreciaton_t-1 + PPE_t-1)) / (Depreciation_t / (Depreciaton_t + PPE_t))
=(0 / (0 + 1729.578)) / (0 / (0 + 1590.382))
=0 / 0
=1

Note: If the Depreciation, Depletion and Amortization data is not available, we assume that the depreciation rate is constant and set the Depreciation Index to 1.

6. SGAI = Sales, General and Administrative expenses Index

The ratio of Selling, General, & Admin. Expense(SGA) to Sales in year t relative to year t-1.

SGA expenses index > 1 means that the company is becoming less efficient in generate sales.

SGAI=(SGA_t / Sales_t) / (SGA_t-1 /Sales_t-1)
=(1036.433 / 2390.169) / (1191.634 / 2072.899)
=0.433623 / 0.574864
=0.7543

7. LVGI = Leverage Index

The ratio of total debt to Total Assets in year t relative to yeat t-1.

An LVGI > 1 indicates an increase in leverage

LVGI=((LTD_t + CurrentLiabilities_t) / TotalAssets_t) / ((LTD_t-1 + CurrentLiabilities_t-1) / TotalAssets_t-1)
=((288.697 + 2247.538) / 5117.183) / ((464.066 + 3200.147) / 7055.301)
=0.495631 / 0.519356
=0.9543

8. TATA = Total Accruals to Total Assets

Total accruals calculated as the change in working capital accounts other than cash less depreciation.

TATA=(IncomefromContinuingOperations_t - CashFlowsfromOperations_t) / TotalAssets_t
=(NetIncome_t - NonOperatingIncome_t - CashFlowsfromOperations_t) / TotalAssets_t
=(-607.565 - 0 - 343.958) / 5117.183
=-0.185947

An M-Score of equal or less than -1.78 suggests that the company is unlikely to be a manipulator. An M-Score of greater than -1.78 signals that the company is likely to be a manipulator.

Luoxin Pharmaceuticals Group Stock Co has a M-score of -4.20 suggests that the company is unlikely to be a manipulator.


Luoxin Pharmaceuticals Group Stock Co Beneish M-Score Related Terms

Thank you for viewing the detailed overview of Luoxin Pharmaceuticals Group Stock Co's Beneish M-Score provided by GuruFocus.com. Please click on the following links to see related term pages.


Luoxin Pharmaceuticals Group Stock Co (SZSE:002793) Business Description

Traded in Other Exchanges
N/A
Address
85 Faraday Road, Floor 1-3, Building 1, Building 2, Pilot Free Trade Zone, Shanghai, CHN, 201203
Luoxin Pharmaceuticals Group Stock Co Ltd is a pharmaceutical enterprise engaged in research and development, production, and trade of new drugs. It manufactures drugs for various diseases including tumor, respiratory, gastrointestinal, endocrine, cardiovascular, nervous system, antimicrobial infection, among others.
Executives
Ye Bang Mi Supervisors
Fang Xiu Bao Directors, executives
Zhu Fu Lin Directors, executives
Chen Li Supervisors
Yao Liang Directors, executives

Luoxin Pharmaceuticals Group Stock Co (SZSE:002793) Headlines

No Headlines